NCT05880849 is a Phase 1 clinical trial of Choline in Alzheimer Disease, sponsored by Paul E Schulz.

Who is sponsoring NCT05880849?

NCT05880849 is sponsored by Paul E Schulz.

What drugs are being tested in NCT05880849?

Interventions in NCT05880849: Choline.

What condition does NCT05880849 study?

NCT05880849 studies Alzheimer Disease.

Is NCT05880849 still recruiting?

NCT05880849 is currently completed. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT05880849

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Choline Effects - Pre-symptomatic AD

Completed Phase 1 Last updated 2 February 2026

What this trial tests

Phase 1 trial testing Choline in Alzheimer Disease in 15 participants. Completed in 10 October 2025.

Timeline

26 June 2023

Primary endpoint
1 July 2025

10 October 2025

Quick facts

Lead sponsor	Paul E Schulz
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	26 June 2023
Primary completion	1 July 2025
Estimated completion	10 October 2025
Sites	1 location across United States

Drugs / interventions tested

Choline (Choline) — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Paul E Schulz — full company profile →

Who can join

Adults 55 to 80, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the safety, tolerability, and effects of choline in people with increased risk of Alzheimer's Disease (AD), also known as pre-symptomatic AD. Choline is a dietary supplement, but is being investigated to see if it has any effects on the progression to AD.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Alzheimer's disease drug development pipeline: 2024.
Cummings J, Zhou Y, Lee G, Zhong K, et al · · 2024 · cited 209× · PMID 38659717 · DOI 10.1002/trc2.12465
Lipids as Emerging Biomarkers in Neurodegenerative Diseases.
Wei J, Wong LC, Boland S. · · 2023 · cited 46× · PMID 38203300 · DOI 10.3390/ijms25010131
The Energetic Collapse of the Alzheimer's Brain: Metabolic Inflexibility Across Cells and Networks.
Constantino NJ, Ashley CC, Macauley SL. · · 2025 · cited 2× · PMID 41231438 · DOI 10.1111/jnc.70294
Alzheimer's disease drug development pipeline: 2026.
Cummings JL, Zhou Y, Yang Y, Zhong K, et al · · 2026 · PMID 42095064 · DOI 10.1002/trc2.70251
Vitamin deficiencies and Alzheimer's disease: evidence and implications for supplementation.
Miteva MT, Laurenti D, Mattioli R, Di Risola D, et al · · 2026 · PMID 41769656 · DOI 10.3389/fnut.2026.1676497

Verify or expand the search:

Other trials of Choline

Trials testing the same drug.

NCT06379971 — Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development · Phase 1 · recruiting
NCT06924541 — Choline Dose Ranging in Postmenopausal Women · NA · recruiting
NCT05076682 — Reverse Triple Negative Immune Resistant Breast Cancer · Phase 2 · recruiting
NCT07264257 — Choline and Brain Functioning in Postmenopausal Women · NA · completed
NCT04764162 — Choline and Cardiometabolic Health · NA · completed

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05880849 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paul E Schulz
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05880849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing